Intellia Therapeutics stock price target lowered to $45 by Wells Fargo

Wells Fargo lowered its price target on Intellia Therapeutics (NTLA) to $45 from $50, while maintaining an Overweight rating, reflecting updated development timelines for its key programs. The firm noted Intellia's nex-z (ATTR-PN) study enrollment completion is now expected by H1 2026 for a potential 2028 BLA filing, while its lonvo-z (HAE) program rapidly completed recruitment, indicating strong demand for the therapy. Despite the stock trading significantly below analyst targets, Intellia recently reported a Q2 earnings beat, but analysts emphasize the company's rapid cash burn as a critical factor despite its strong cash position.

Analysis

Intellia Therapeutics (NTLA) presents a mixed but cautiously optimistic outlook following recent analyst actions and operational updates. Both Wells Fargo and Leerink Partners have trimmed their price targets to $45 and $41 respectively, while crucially maintaining their bullish Overweight and Outperform ratings. The primary catalyst for these adjustments is the revised development timeline for the nex-z program, with a Biologics License Application (BLA) now projected for 2028 or earlier, pushing out a key value driver. This is counterbalanced by significant positive momentum in the lonvo-z (HAE) program, which completed recruitment for its HAELO study in just four months, indicating strong demand as patients switch from leading therapies. Financially, Intellia posted a solid Q2 2025 earnings beat, with EPS of -$0.98 and revenue of $14.24 million both surpassing forecasts. However, despite a strong balance sheet characterized by more cash than debt and a current ratio of 4.9x, the company's rapid cash burn is highlighted as a critical risk factor that tempers enthusiasm over its clinical progress and long-term pipeline potential.

Key Decisions for Investors

• Investors should weigh the company's high cash burn and the extended development timeline for its nex-z treatment against the strong demonstrated demand for its lonvo-z candidate and the recent Q2 earnings surprise.
• It is critical to monitor Intellia's quarterly cash consumption and cash runway, as this is the primary risk factor cited alongside the multi-year path to potential commercialization for its key assets.
• The upcoming presentation of long-term Phase 1 data in September 2025 represents a significant near-term catalyst that could impact sentiment and validate the platform's durability.
• Note the substantial gap between the current stock price ($11.46) and revised analyst price targets ($41-$45), which suggests the market is heavily discounting execution risk while analysts maintain a view of long-term value.